医学会议分类导航
 
 
领域国际医学会议网公众号
 
首页  
2022年第19届国际胃肠道肿瘤学会年会(ISGIO)
     
 

◆ 会议时间:2022年9月30日至10月1日
◆ 会议地点:美国 纳什维尔

 

◆ 会议简介:

2022年第19届国际胃肠道肿瘤学会(ISGIO)年会将于022年9月30日至10月1日在美国纳什维尔 以线上线下混合会议形式举行。ISGIO胃肠道肿瘤学大会是国际胃肠肿瘤学会(ISGIO)的官方年度会议,大会将展示和讨论胃肠道癌症研究领域的最新进展,以及探讨与胃肠道癌患者护理相关的关键议题。

国际胃肠道肿瘤学会(ISGIO)是全球第一个致力于胃肠道肿瘤研究与教育的非营利性组织,现在全球拥有1500多名成员。ISGIO的使命是建立一个交流胃肠道肿瘤学前沿研究和实践问题的权威论坛;鼓励年轻的研究人员参与胃肠道肿瘤研究;促进全球GI肿瘤的研究和教育;宣促进新的GI肿瘤相关知识和发现的及时交流和传播;在全球范围内促进GI肿瘤的卓越治疗;减轻胃肠道癌症的社会负担;等等。未经许可禁止复制摘录转载本站任何内容-国际医学会议网(lingyuint.com).

ISGIO 2022 - 19th Annual Meeting of the International Society of Gastrointestinal Oncology
Date: September 30 - October 1, 2022 - Eastern Time
Venue: Loews Vanderbilt Nashville, USA

 

Physicians’ Education Resource®, LLC (PER®), is pleased to present the 18th Annual Meeting of the International Society of Gastrointestinal Oncology®, a 2-day, multidisciplinary educational conference dedicated to  presenting and discussing the latest advances in the broad field of  gastrointestinal (GI) cancer research, as well as critical issues  relevant to the care of people with GI cancer.

GI malignancies are often difficult to treat because of their  heterogeneity, and the optimal management of these tumors often requires  a high level of multidisciplinary cooperation and multimodality  treatment regimens.

This highly engaging conference brings together world-renowned experts  from different disciplines to educate clinicians using a combination of  case-based learning, debates, panel discussions, and didactic segments.  Throughout the educational sessions, attendees will have numerous  opportunities to interact with the presenting faculty.

The learning objectives of this program are:

  • Describe current standards of care for treatment of GI malignancies
  • Discuss recent advances and innovations in the management of GI malignancies
  • Analyze clinical trial data that may impact treatment decision-making in GI oncology
  • Implement a multimodal approach to the treatment of GI malignancies,  including gastric, pancreatic, and colorectal cancers, hepatocellular  carcinoma, and cholangiocarcinoma

The target audience for this activity is directed toward oncologists and  practitioners of oncology subspecialties, along with surgeons,  radiologists, general scientists, young investigators, nurses, and  pharmacists with an interest in GI oncology. Other health care  professionals interested in the treatment of these malignancies are also  invited to participate.

 

摘要提交:

Submission Deadline August 5, 202211:59 PMET

点此提交摘要>>>Submit Abstract>>>

The program chair of the 19th Annual Meeting of the International Society of Gastrointestinal Oncology® invites you to submit your abstracts to this year's 19th Annual Meeting of the International Society of Gastrointestinal Oncology®.

All poster abstract submissions must be made electronically through the 19th Annual Meeting of the International Society of Gastrointestinal Oncology® online abstract submission system.

Your abstract should be a short description of your work and contain all the elements necessary to define your goals and results to the reader. Authors will be required to disclose all financial relationships through the online system, to ensure quality and unbiased presentations. The formal poster session is not designated for credit.

Share your research or best practices with your peers. Categories of submission include the following:

  • Colorectal cancer
  • Esophageal/gastric cancer
  • Hepatobiliary cancer
  • Pancreatic cancer
  • Neuroendocrine tumors
  • Other GI-related oncology

The program chairs will evaluate the scientific quality of the submitted abstracts on the basis of the following criteria: novelty of the research, significance of the findings, and clarity. Incomplete abstracts will not be reviewed. Please note that we will consider case series of more than 5 reports, but we are not accepting case series of <5 patients and single-patient case reports.

Notification of acceptance or regret will be delivered via email to the presenter(s) of each poster abstract by September 9, 2022. Please note that an author is required to be present during the poster session.

If accepted for presentation, abstracts and posters will be available for viewing online on the 2022 conference website during and after the conference. The posters will be displayed for the length of the conference. The presentation at the 19th Annual Meeting of the International Society of Gastrointestinal Oncology® should reflect the submitted abstract, abstract title, authorship, and content.

All presenters must register to attend the 2022 19th Annual Meeting of the International Society of Gastrointestinal Oncology®.

Submission Process

  • Complete the abstract template provided on the 2022 19th Annual Meeting of the International Society of Gastrointestinal Oncology® website.
  • Limit is 2500 characters (abstract body, including spaces and 1 table).

Components of the Abstract Body Limit: 2500 words (1 table is allowed)

Abstracts of Clinical Trials With Results to Be Presented

  • Background/Significance: What was the problem, and why was it  important? What knowledge are you building on? What was the intent or  goal of the study? What did you want to learn?
  • Materials and Methods: What was the trial design? What was the sample?  What instruments were used? How were data collected and analyzed?
  • Results: What were the findings?
  • Conclusions: What do the findings mean?

Abstracts of Clinical Trials in Progress (ie, results not yet available)

  • Background/Significance: What is the problem, and why is it important?  What knowledge are you building on? What are the objectives of the  study? What do you want to learn?
  • Design and Methods: What is the trial design? What is the study  population (including inclusion and exclusion criteria)? What is the  statistical design? What are the study end points?
  • Status: What is the current status of the trial (eg, enrollment  status, participating study centers, anticipated completion date)?

Abstract Questions

Please submit any questions pertaining to abstract submissions to abstracts@gotoper.com using the subject line “ISGIO Abstract QUESTION.”

Author Consent and Waiver of Claims

  • Each abstract author agrees and certifies that he or she:
    • Waives any and all claims against Physicians' Education Resource®, LLC (PER®), sponsor of the 19th Annual Meeting of the International Society of Gastrointestinal Oncology®,  and any review arising out of or relating to the abstract submission  and review process, including but not limited to peer review and the  grading of abstracts.

Answers to Frequently Asked Questions

  • Abstracts in the following categories will also be considered for presentation:
  • Basic science (preclinical research), pharmacokinetics/pharmacodynamics, and health economic outcomes research
  • Case series of ≥5 patients (case series of <5 patients and single-patient case reports are not accepted)
  • Encore presentations (abstract and poster must indicate where originally presented)
  • Late-breaking abstracts
  • Literature reviews
  • Research abstracts funded by for-profit organizations, including biotech and pharmaceutical
  • Trials in progress:
    • Trial must be open to accrual
    • Abstracts/posters for the “Trials in Progress” category cannot include end point data from the trial. If end point data are to be presented, please submit under the “Abstracts of Clinical Trials With Results to Be Presented” category.
  • Abstracts are currently accepted only for poster presentation, not oral presentation
  • Abstracts are not published, but are posted to the attendee eSyllabus
  • Pharmaceutical industry authors are allowed to present abstracts
  • A non-named author can present a poster if written permission to do so is provided by the lead author

 

Abstract Format

  • The title of the abstract should be brief and objectively describe the study. Do not use nonstandard abbreviations and commercial names (use generic names only). Use title case and capitalize all nouns, verbs, adverbs, and conjunctions of 4 letters or more. Do not capitalize a coordinating conjunction, an article, or a preposition of 3 or fewer letters, except when it is the first or last word in a title. Keep letters lowercase if the lowercase letters have a specific meaning, such as pH or mL. Do not put a period at the end of the title.
  • No more than 15 authors can be listed with institutional affiliations, cities, and countries only. Mailing addresses and academic degrees should not be mentioned in the author's list. For cooperative study groups, you may give the name of the group instead of individual institutional affiliations or include the name of the group in the title of the abstract.
  • First Author (Presenting Author): The name, institution, telephone number, and email address of the First Author are required. The First Author (Presenting Author) will receive all future correspondence from PER®.
  • Abstracts should be structured in such a way as to include the following sections:
    • Abstracts of Clinical Trials With Results to Be Presented (4 sections)
      1. Background: an introductory sentence indicating the purpose of the study
      2. Material and Methods: a brief description of pertinent experimental procedures
      3. Results: a summary of the results of the research
      4. Conclusions: a statement of the main conclusions
    • Abstracts of Clinical Trials in Progress (ie, results not yet available; 3 sections)
      • Background: an introductory sentence indicating the purpose of the study
      • Design and Methods: a brief description of pertinent experimental procedures
      • Status: a summary of the status of the study
  • Abstracts  should not exceed 2500 characters (body of the abstract, including  spaces and table).
  • Only 1 data table is  permitted in the body of the abstract. Illustrations and/or figures are not allowed and will be deleted if submitted.
  • Standard abbreviations may be used and must be spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lowercase. Commercial names may be included in the abstract text in parentheses, directly following the generic name at first use. For example, "generic (Commercial).” Do not use trademark symbols.
  • Abstracts cannot be revised once submitted.
  • The abstract must be submitted in English.

 

 

 

注册费:

Live Registration Fees - 现场注册费 Advanced On-site
Physicians $129 $179
Fellows* $69 $99
Nurses, PAs, Other Health Care Professionals $59 $79
Industry** $449 $499

 

Virtual Registration Fees - 虚拟注册费 Advanced On-site
Physicians $75 $125
Fellows* $35 $75
Nurses, PAs, Other Health Care Professionals $35 $75
Industry** $329 $329

*FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount. Cannot be combined with other discounts/coupon codes.

**INDUSTRY is defined by PER® as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.

For registration assistance, please email info@gotoper.com, or call +1-(888)-949-0045 or +1-(609)-378-3701.

A cancellation fee of 25% will be assessed on refunds requested prior to August 5, 2022, and a 50% fee on refunds requested on August 6, 2020 through September 2, 2022. No refunds will be made after September 2, 2022. There is no charge for substitution. Substitutions can only be applied to the same conference and only two substitutions will be honored.

 

◆ 参会对象:肿瘤学家/医师和肿瘤学亚专业的从业者,以及对胃肠道肿瘤学感兴趣的外科医生、放射科医生、普通科学家、年轻调查员、护士和药剂师,以及其他对治疗这些恶性肿瘤感兴趣的医疗保健专业人员。

 
 
※相关服务※
会议注册服务:30美金起/人/次(服务费)+ 会议注册费(按官方规定收取,注册类别请咨询客服);
出境签证服务:1650元人民币/人/次(美国,含签证费),其它国家咨询客服;
大会投稿服务:30美金/人/次,官方收取费用另计(如有);
会员申请服务:30-100美金/人/次;

团组参会、行程定制,以及需要其它服务(如接送机等),请直接联系客服。


 
咨询报名:
李老师
400-089-1003(微信扫描右侧二维码咨询)
 
 
领域国际医学会议网——专注专业的国际医学会议服务商,专业服务医学相关群体!
 
  领域国际医学会议网介绍/联系  
版权所有:领域国际医学会议网 未经许可禁止复制转载摘录镜像本站任何内容! 隐私政策/版权/免责声明 | 联系我们